Business Wire

HITHIUM

Share
Hithium Launches Eastern Europe's Largest BESS Project

Stationary battery manufacturer Hithium has successfully deployed the largest battery energy storage system (BESS) project in Eastern Europe to date, with a capacity of 55MWh. This solar plus storage project was realized completely by EPC company Solarpro, in Razlog, Southwestern Bulgaria, where the project is located.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709299471/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hithium BESS project in Razlog, Bulgaria (Photo: Business Wire)

The new facility officially went live in early June, with the delivery of Hithium’s 16 energy storage containers, each with a capacity of 3.44MWh, to Solarpro. Solarpro is a leading technological provider of solutions for the generation and storage of energy within whole Europe.

Hithium ∞ Block 3.44MWh container

The Hithium ∞ Block 3.44MWh container is a liquid-cooled battery storage system based on Hithium prismatic LFP BESS cells with a 280Ah capacity and a high cyclic lifetime. It is specially optimized for use in stationary battery storage systems with high standards of safety, reliability, and performance. The system’s low levelized cost of storage (LCOS), combined with excellent thermal management, improves energy throughput by ensuring optimal operating temperature and high energy density. It also integrates with a thermal management system, fire protection system, battery management system (BMS), and more.

As Kelson Li, Hithium Senior Director of Sales of DACH, Northern & Eastern Europe said: "We are honored to partner with Solarpro. By providing comprehensive technical and after-sales support throughout the project lifecycle, we aim to foster local expertise and expand the network in Europe. We believe our collaboration with Solarpro will help to accelerate the renewable energy transition and make a positive impact in the region."

Krasen Mateev, CEO of Solarpro adds: "As strategic partners in this landmark project, we are excited to collaborate with Hithium in bringing this significant BESS utility to operation. This undertaking reflects Solarpro’s dedication to advance renewable energy infrastructure in Eastern Europe, ensuring a sustainable energy future for generations to come."

Hithium’s Commitment to the European Market

Hithium is committed to fostering a stronger and more collaborative relationship within the local European market. To this end, the company has set up a regional office in Munich, Germany, offering local support and services. Furthermore, Hithium has formed strategic alliances with other industry leaders, including Scan Global Logistics, to offer unparalleled transportation services, and CarbonX, to advance the energy sector in terms of environmental responsibility and technological advancement.

About Hithium

Hithium is a leading manufacturer of top-quality stationary energy storage products for utility-scale as well as commercial and industrial applications. With more than 20GWh BESS projects shipment up to date. Hithium took the top 5 global market shares and was ranked as the Tier 1 BESS supplier. With four distinct R&D centers and multiple “intelligent” production facilities, Hithium’s innovations include groundbreaking safety improvements to its lithium-ion batteries as well as increases in lifecycle. With decades of cumulative experience in the field among its founders and senior executives, Hithium leverages its specialization in BESS to deliver partners and customers unique advances in energy storage. The company is headquartered in Xiamen, China, with locations in Shenzhen, Chongqing, Munich, Dubai, New York and California.

About Solarpro

Solarpro is a multi-technology integrator with expertise in hybrid projects that include photovoltaic (PV), wind, battery energy storage systems (BESS), and hydrogen solutions. As a leading EPC contractor with 15 years of experience and a team of over 1,000 professionals, Solarpro has designed, built, and integrated PV plants with a total capacity exceeding 7 GW. The company is a technological innovator, excelling in engineering and digitalizing renewable projects, transforming them into dispatchable and flexible assets aligned with energy market developments. Committed to sustainability, Solarpro has further developed expertise in recycling PV modules and batteries to utilize damaged or polluted land, transforming them into state-of-the-art clean energy plants.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709299471/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e

AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release

Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release

Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its

Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release

4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye